Header Logo

Connection

JOHN VIERLING to Interferon-alpha

Back to Details
This is a "connection" page, showing publications JOHN VIERLING has written about Interferon-alpha.
JOHN VIERLING
Connection Strength
3.274
Interferon-alpha
  1. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol. 2014 Aug; 61(2):200-9.
    View in: PubMed
    Score: 0.378
  2. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. J Hepatol. 2014 Apr; 60(4):748-56.
    View in: PubMed
    Score: 0.370
  3. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int. 2014 May; 34(5):707-19.
    View in: PubMed
    Score: 0.365
  4. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology. 2012 Aug; 56(2):464-73.
    View in: PubMed
    Score: 0.333
  5. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl. 2003 Nov; 9(11):S79-89.
    View in: PubMed
    Score: 0.183
  6. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016; 15(6):834-845.
    View in: PubMed
    Score: 0.113
  7. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. J Viral Hepat. 2016 Feb; 23(2):80-8.
    View in: PubMed
    Score: 0.104
  8. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-na?ve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther. 2015 Oct; 42(7):829-44.
    View in: PubMed
    Score: 0.103
  9. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015 Jul; 63(1):30-7.
    View in: PubMed
    Score: 0.100
  10. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
    View in: PubMed
    Score: 0.097
  11. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun; 64(6):948-56.
    View in: PubMed
    Score: 0.096
  12. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014 Aug; 147(2):366-76.e6.
    View in: PubMed
    Score: 0.094
  13. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am. 2014 Jan; 98(1):17-38.
    View in: PubMed
    Score: 0.093
  14. PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):524-37.
    View in: PubMed
    Score: 0.089
  15. JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-na?ve HCV genotype 1/4 patients. Hepatology. 2013 Aug; 58(2):514-23.
    View in: PubMed
    Score: 0.089
  16. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15; 381(9883):2100-7.
    View in: PubMed
    Score: 0.088
  17. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-a2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial. Antivir Ther. 2013; 18(3):387-97.
    View in: PubMed
    Score: 0.087
  18. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol. 2013 Mar; 58(3):479-87.
    View in: PubMed
    Score: 0.086
  19. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol. 2013 Jan; 11(1):81-87.e4; quiz e5.
    View in: PubMed
    Score: 0.085
  20. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011 Aug; 15(3):515-36.
    View in: PubMed
    Score: 0.078
  21. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28; 376(9742):705-16.
    View in: PubMed
    Score: 0.073
  22. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006 Jun; 35(2):463-86.
    View in: PubMed
    Score: 0.055
  23. Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs. 2002 Dec; 25(12):1189-93.
    View in: PubMed
    Score: 0.043
  24. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr. 1995 Nov; 127(5):815-8.
    View in: PubMed
    Score: 0.026
  25. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61(6):1238-46.
    View in: PubMed
    Score: 0.024
  26. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31; 364(13):1207-17.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.